Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with the emergence of AR– neuroendocrine prostate cancer (NEPC) coupled with mutations/deletions in PTEN, TP53, and RB1 and the overexpression of DNMTs, EZH2, and/or SOX2. To...

Full description

Bibliographic Details
Main Authors: W. Nathaniel Brennen, Yezi Zhu, Ilsa M. Coleman, Susan L. Dalrymple, Lizamma Antony, Radhika A. Patel, Brian Hanratty, Roshan Chikarmane, Alan K. Meeker, S. Lilly Zheng, Jody E. Hooper, Jun Luo, Angelo M. De Marzo, Eva Corey, Jianfeng Xu, Srinivasan Yegnasubramanian, Michael C. Haffner, Peter S. Nelson, William G. Nelson, William B. Isaacs, John T. Isaacs
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-04-01
Series:JCI Insight
Subjects:
Oncology
Online Access:https://doi.org/10.1172/jci.insight.146827

Internet

https://doi.org/10.1172/jci.insight.146827

Similar Items